Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Tax Provisions of $2.8 million for Q1 2026, up 2536.28% year-over-year from $104427.3 in Q1 2025, and up 1788.96% quarter-over-quarter from -$163000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2026) Analysis & Trends
Protalix BioTherapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Tax Provisions rose 2536.28% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.7 million (up 115.0% YoY), while the FY2025 annual figure was $105000.0, down 91.41% from the prior year.
- Tax Provisions for Q1 2026 stood at $2.8 million, up from -$163000.0 in the prior quarter.
- The five-year high for Tax Provisions was $3.4 million in Q2 2023, with the low at -$1.9 million in Q4 2023.
- The 4-year median for Tax Provisions is $133000.0 (2023), against an average of $432846.2.
- The sharpest annual moves came in 2024 and 2026: Tax Provisions tumbled 170.77% in 2024, then surged 2536.28% in 2026.
- Protalix BioTherapeutics' Tax Provisions stood at -$1.9 million in 2023, then jumped by 154.85% to $1.1 million in 2024, then tumbled by 115.41% to -$163000.0 in 2025, then soared by 1788.96% to $2.8 million in 2026.
- Business Quant data shows PLX's Tax Provisions at $2.8 million in Q1 2026, -$163000.0 in Q4 2025, and -$175000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | - |
| 10 | Protalix BioTherapeutics | 189.57 Mn | 148.91 Mn | 12.13 Mn | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.08 Mn |
| Mar 31, 2026 | 2.75 Mn |
| Dec 31, 2025 | -163,000.00 |
| Sep 30, 2025 | -175,000.00 |
| Jun 30, 2025 | 266,000.00 |
| Mar 31, 2025 | -113,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 371,000.00 |
| Jun 30, 2024 | -69,000.00 |
| Mar 31, 2024 | -138,000.00 |
| Dec 31, 2023 | -1.93 Mn |
| Sep 30, 2023 | 133,000.00 |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 195,000.00 |